Vaginal Dryness: What Could Be Causing It and What Actually Helps

Why Vaginal Dryness Happens: The Short Answer

Vaginal lubrication depends almost entirely on estrogen. Estrogen keeps the vaginal epithelium thick, well-glycogenated, and supplied with the transudation fluid that creates natural moisture. When estrogen falls, for any reason, the tissue thins, loses rugae, and produces less fluid. The medical term for the full syndrome is genitourinary syndrome of menopause (GSM), though that label is misleading because the same tissue changes happen in premenopausal women whenever estrogen drops below the threshold that sustains vaginal health.

Understanding the cause matters because the treatment differs. A 28-year-old on an aromatase inhibitor for breast cancer needs a different conversation than a 52-year-old in natural menopause or a 31-year-old six weeks postpartum.

The Estrogen Threshold: Why Your Hormones Are Central

The vaginal mucosa contains a dense concentration of estrogen receptors. Research published in Menopause found that among women with GSM symptoms, only about 7% had received prescription treatment despite the condition profoundly affecting quality of life. That gap exists partly because women and clinicians alike assume dryness is inevitable rather than treatable.

How Low Is "Too Low"?

Serum estradiol levels do not map perfectly onto vaginal symptoms. Some women experience significant dryness at levels that others tolerate without complaint. The vaginal pH is a more clinically useful marker: a pH above 5.0 generally indicates estrogen deficiency in the vaginal environment, while a healthy premenopausal pH sits between 3.8 and 4.5. The Menopause Society (formerly NAMS) 2023 position statement on GSM defines GSM as a chronic, progressive condition requiring ongoing management rather than one-time treatment.

The Lactobacillus Connection

Estrogen promotes Lactobacillus dominance in the vaginal microbiome. When estrogen falls, Lactobacillus species decline, vaginal pH rises, and the tissue becomes more prone to irritation and secondary infection. This is why vaginal dryness and recurrent bacterial vaginosis often travel together in perimenopause and postmenopause.

Causes by Life Stage

Reproductive Years (Roughly Ages 15 to 45)

Vaginal dryness in women who are still cycling regularly is underrecognized. Several causes are worth naming explicitly.

Hormonal contraception. Combined oral contraceptives raise sex hormone-binding globulin (SHBG), which binds free testosterone and also reduces circulating estrogen at the vaginal tissue level. A 2020 study in the Journal of Sexual Medicine found that women on combined pills reported significantly lower vaginal lubrication scores than non-users, with effects that persisted for months after stopping in some cases. Progestin-only methods, particularly the 52 mg levonorgestrel IUD (Mirena), generally have less impact on vaginal tissue than pills, though the etonogestrel implant (Nexplanon) suppresses ovulation enough to reduce estrogen in some users.

Hyperprolactinemia. Elevated prolactin, whether from a pituitary adenoma, antipsychotic medication, or primary hypothyroidism, suppresses the hypothalamic-pituitary-ovarian axis. The resulting low estrogen state produces vaginal dryness identical to menopause. Checking a prolactin level is a routine step in evaluating dryness in a woman who is not perimenopausal and not on hormonal contraception.

Premature ovarian insufficiency (POI). POI affects approximately 1% of women under age 40 and produces full estrogen deficiency with all its consequences, including GSM symptoms, often years before a woman expects any menopause-related change.

Sjögren syndrome and other autoimmune conditions. Sjögren syndrome is a systemic autoimmune disease that preferentially affects exocrine glands. Women make up about 90% of those diagnosed. Vaginal dryness in Sjögren is both a direct glandular effect and a consequence of secondary estrogen disruption. ACOG Committee Opinion 659 recognizes vaginal dryness as a quality-of-life issue that warrants treatment even in populations where systemic hormones are restricted.

Medications in reproductive-age women.

• SSRIs and SNRIs reduce serotonin-driven central arousal and directly impair vaginal lubrication through a non-estrogen pathway. A 2016 analysis in CNS Drugs estimated that sexual dysfunction, including lubrication problems, affects 30 to 70% of women taking SSRIs, depending on the agent and dose.
• Isotretinoin (Accutane) reduces sebaceous and mucosal secretions broadly. Vaginal dryness is a reported but underacknowledged side effect; the FDA label focuses on mucocutaneous effects but vaginal mucosa is histologically similar.
• Antihistamines (diphenhydramine, loratadine, fexofenadine) have anticholinergic or anti-secretory effects that reduce all mucosal secretions, including vaginal moisture. The effect is dose-dependent and often reversible.

PCOS. Women with PCOS have androgen excess, but androgen excess does not reliably protect vaginal tissue from dryness. Anovulatory cycles mean estrogen exposure is often unopposed and dysregulated. Some women with PCOS, especially those on metformin alone without ovulatory restoration, experience intermittent low-estrogen states that produce dryness. Women with PCOS who use combined oral contraceptives for cycle regulation may experience contraceptive-related dryness as described above.

Trying to Conceive (TTC)

The luteal phase of the natural cycle produces the driest vaginal environment of the month. Progesterone thickens cervical mucus and reduces vaginal transudation. Women trying to conceive often notice significant dryness in the two weeks between ovulation and their period. Standard water-based lubricants may impair sperm motility; if lubrication is needed during the TTC phase, ASRM recommends hydroxyethylcellulose-based lubricants (such as Pre-Seed) or canola oil as options with less sperm toxicity than traditional products.

Postpartum and Lactation

This is one of the most common and least-discussed causes of vaginal dryness in young women. After delivery, estrogen drops to near-castrate levels regardless of whether you breastfeed. If you breastfeed exclusively, prolactin remains elevated and actively suppresses the return of ovarian estrogen production for the full duration of lactation. Vaginal dryness during this period can be severe enough to make intercourse painful (dyspareunia) for months.

The good news is that low-dose vaginal estrogen is considered compatible with breastfeeding. The Menopause Society's 2023 GSM position statement notes that vaginal estrogen products produce minimal systemic absorption, and the small amount absorbed is unlikely to affect milk composition or infant safety at standard doses (typically 0.5 to 1 g of conjugated estrogen cream or a 10 mcg estradiol tablet/ring). Clinical guidance generally recommends starting with vaginal moisturizers and lubricants first, reserving vaginal estrogen for cases where non-hormonal options are inadequate.

Perimenopause (Typically Ages 45 to 52, but Can Start Earlier)

Perimenopause is the stretch of hormonal variability before the final menstrual period. Estrogen does not drop steadily; it oscillates, sometimes spiking higher than premenopause before ultimately declining. Vaginal symptoms often begin while cycles are still regular, because the troughs in estrogen become lower and longer. Many women are surprised to develop dyspareunia or dryness while still having periods.

A 2019 study in JAMA Internal Medicine found that genitourinary symptoms increased progressively across the menopausal transition, with dyspareunia affecting roughly 41% of postmenopausal women compared with about 17% in premenopause. The gradient through perimenopause is real and measurable.

Postmenopause

After the final menstrual period, ovarian estrogen production falls by approximately 90%. The Study of Women's Health Across the Nation (SWAN) documented that vaginal dryness becomes one of the most bothersome symptoms for postmenopausal women, with prevalence increasing over time rather than stabilizing the way hot flashes do. Unlike hot flashes, GSM does not improve without treatment; it progresses.

Systemic menopausal hormone therapy (MHT) alleviates vaginal dryness in most postmenopausal women, but vaginal estrogen alone is sufficient and often preferable for women whose only symptom is GSM rather than vasomotor or systemic symptoms. ACOG Practice Bulletin 141 supports both systemic and local estrogen for GSM, with local vaginal estrogen preferred when systemic treatment is not otherwise indicated.

Cancer Treatment and Medically Induced Menopause

This is an underserved area. Women undergoing treatment for hormone receptor-positive breast cancer face severe iatrogenic vaginal dryness from multiple angles:

• Aromatase inhibitors (letrozole, anastrozole, exemestane) suppress residual estrogen production in postmenopausal women to near-zero. GSM in this context is often more severe than natural menopause.
• Tamoxifen has mixed estrogenic/antiestrogenic tissue effects. It may cause vaginal dryness or, paradoxically, discharge depending on individual receptor expression.
• GnRH agonists (leuprolide, goserelin), used for premenopausal breast cancer, endometriosis, or uterine fibroids, produce a medical menopause with rapid and severe estrogen deficiency.
• Chemotherapy can cause premature ovarian insufficiency, either temporarily or permanently, depending on agent, dose, and age.

Non-hormonal vaginal moisturizers are first-line in this population. The 2021 ACOG Committee Opinion on sexual health and cancer acknowledges the significant quality-of-life burden of treatment-related GSM and supports individualized management. For women with breast cancer, vaginal DHEA (prasterone/Intrarosa) and ospemifene are under active investigation as non-estrogenic options, though current guidelines from major oncology societies do not yet endorse routine vaginal estrogen in ER-positive breast cancer without oncologist input.

Diagnosis: What Your Clinician Will Do

Vaginal dryness is a clinical diagnosis, but the workup depends on whether an obvious cause is already identified.

History

Your clinician will ask about:

• Menstrual cycle status and regularity
• Contraceptive method
• Recent pregnancy or breastfeeding
• Medications (SSRIs, antihistamines, isotretinoin, aromatase inhibitors, GnRH agonists)
• Autoimmune symptoms (dry eyes, dry mouth, joint pain)
• Thyroid history
• Cancer treatment history
• Skin conditions that affect mucous membranes (lichen sclerosus, lichen planus)

Physical Examination

Pelvic examination looking at vaginal rugae (the folds that flatten with atrophy), vaginal wall color (pale or erythematous rather than pink and moist), cervical position (the cervix shortens and retracts in menopause), and any signs of lichen sclerosus or lichen planus (white patches, architectural change, fissures at the introitus).

Vaginal pH testing using a simple strip is inexpensive and informative. A pH above 5.0 in a woman not currently on antibiotics or semen-exposed in the past 24 hours supports an estrogen-deficient state.

Laboratory Tests

Not always needed, but may include:

• FSH and estradiol: FSH above 40 IU/L plus estradiol below 30 pg/mL on two occasions 4+ weeks apart confirms POI or menopause in the right clinical context
• Prolactin: to rule out hyperprolactinemia
• TSH: thyroid dysfunction can cause secondary hormonal disruption and mucosal symptoms
• ANA, anti-SSA/SSB: if Sjögren syndrome is suspected

Treatment: Matching the Fix to the Cause

The WomanRx Cause-First Treatment Framework for vaginal dryness:

| Cause | First-Line | Second-Line | |---|---|---| | Menopause/postmenopause (GSM) | Vaginal moisturizer + lubricant | Low-dose vaginal estrogen (cream, ring, or tablet) or vaginal DHEA (prasterone) or ospemifene oral | | Perimenopause | As above; systemic MHT if vasomotor symptoms also present | Low-dose vaginal estrogen | | Postpartum/lactation | Vaginal moisturizer + lubricant | Low-dose vaginal estrogen (compatible with breastfeeding at standard doses) | | SSRI/SNRI-related | Lubricant; discuss medication switch or dose reduction with prescriber | Vaginal moisturizer; buspirone augmentation for sexual dysfunction (prescriber discussion) | | Aromatase inhibitor-related | Vaginal moisturizer + lubricant | Vaginal DHEA (oncologist discussion required before any hormonal option) | | Oral contraceptive-related | Lubricant; consider method change | Vaginal moisturizer; switch to non-combined method | | Antihistamine-related | Switch antihistamine if possible; lubricant | Nasal steroid spray instead of oral antihistamine for allergies | | POI | Systemic HRT (not just vaginal estrogen); refer to endocrinology | Vaginal estrogen in addition to systemic | | Sjögren syndrome | Vaginal moisturizer + lubricant | Low-dose vaginal estrogen; rheumatology co-management |

Non-Hormonal Vaginal Moisturizers

These are distinct from lubricants. Moisturizers (Replens, Revaree hyaluronic acid suppositories) are applied every 2 to 3 days and work by maintaining vaginal cell hydration over time. They are not just for sex. A 2018 randomized trial in JAMA Internal Medicine found that vaginal moisturizer was not significantly inferior to low-dose vaginal estrogen for dryness scores in postmenopausal women after 12 weeks, though vaginal pH and cytology improved more with estrogen. This makes moisturizer a reasonable first choice for women who prefer non-hormonal options or who have contraindications.

Low-Dose Vaginal Estrogen

The available formulations are:

• Conjugated estrogen cream (Premarin vaginal cream): 0.5 g applied 2 to 3 times weekly after an initial daily phase
• Estradiol vaginal tablet (Vagifem, Yuvafem): 10 mcg inserted twice weekly after an initial daily phase
• Estradiol vaginal ring (Estring): 7.5 mcg/day released over 90 days
• Estradiol 0.1% cream (Estrace vaginal cream): 0.5 to 1 g, titrated

Systemic absorption from all of these is low. FDA labeling for Vagifem 10 mcg shows serum estradiol levels remaining within the postmenopausal range (<20 pg/mL) in most users, which is why routine progesterone add-back is generally not required for endometrial protection at low vaginal doses, though this is an area of ongoing discussion for women with an intact uterus on longer-term therapy.

Vaginal DHEA (Prasterone / Intrarosa)

Prasterone 6.5 mg vaginal insert, used nightly, converts locally to both estradiol and testosterone in vaginal tissue. It is FDA-approved for dyspareunia due to menopause-related GSM. Because it acts locally via intracrine conversion, serum estradiol and testosterone remain in the postmenopausal range, making it a potential option for some women with a history of hormone-sensitive cancer, though oncology consultation is required before use in that setting.

Ospemifene (Osphena)

Ospemifene is an oral selective estrogen receptor modulator (SERM) taken at 60 mg daily. It acts as an estrogen agonist in vaginal tissue, improving dryness and dyspareunia without requiring intravaginal administration. Key trial data showed significant improvement in the most bothersome symptom at 12 weeks. It is contraindicated in women with known or suspected estrogen-dependent cancers and those at high risk of venous thromboembolism.

Pregnancy and Lactation

Pregnancy: Vaginal dryness during pregnancy is uncommon; estrogen and progesterone are typically elevated. If it does occur, water-based lubricants are safe. Hormonal treatments for vaginal dryness are not used in pregnancy. Ospemifene is contraindicated in pregnancy. Vaginal estrogen products have not been studied in pregnancy and should be avoided on a precautionary basis.

Lactation: As described above, postpartum vaginal dryness from breastfeeding-related hypoestrogenism is extremely common and frequently severe. Low-dose vaginal estrogen (the 10 mcg estradiol tablet or Estring ring) is the preferred hormonal option when non-hormonal measures are insufficient. LactMed notes that systemic estradiol levels from vaginal estrogen at standard low doses remain low enough to make significant milk transfer unlikely, though a brief delay (applying at night after the last nursing session) further reduces any theoretical exposure. Ospemifene and prasterone lack lactation safety data and should be avoided while breastfeeding.

Contraception note: For premenopausal women, vaginal dryness treatment with topical estrogen does not provide contraception. Women who are not postmenopausal and do not want pregnancy need a separate contraceptive method.

Who This Is Right For, and Who Needs a Different Approach

Good candidates for vaginal moisturizer alone:

• Women with mild dryness, any life stage
• Postpartum women preferring non-hormonal management
• Women with mild GSM who prefer to avoid hormones
• Women on aromatase inhibitors (first-line in this group)

Good candidates for low-dose vaginal estrogen:

• Postmenopausal women with moderate to severe GSM
• Postpartum women with severe dryness or dyspareunia who have not responded to moisturizers after 4 to 6 weeks
• Women with POI (in addition to systemic HRT)
• Perimenopausal women whose GSM is ahead of vasomotor symptoms

Needs specialist input first:

• Women on aromatase inhibitors or tamoxifen for breast cancer (oncology discussion required before any hormonal therapy)
• Women with suspected Sjögren syndrome (rheumatology co-management)
• Women with lichen sclerosus or lichen planus (dermatology or vulvar specialist)
• Women with unexplained bleeding alongside dryness (rule out endometrial pathology)
• Women under 40 with suspected POI (endocrinology and/or reproductive endocrinology referral)

Not appropriate without further workup:

• Dryness accompanied by ulceration, abnormal bleeding, or visible lesions needs examination before any treatment
• New dryness in a woman with a history of pelvic radiation needs mucosal assessment to distinguish atrophy from radiation effect or recurrence

When to Worry: Red Flags That Need Same-Week Evaluation

Most vaginal dryness is benign and treatable. These symptoms change that calculus:

• Vaginal bleeding after menopause or between periods
• Visible ulcers, white patches, or architectural changes at the vulva or vaginal introitus
• Rapidly worsening symptoms alongside systemic features (fatigue, joint pain, dry eyes/mouth) suggesting autoimmune disease
• Dryness following recent cancer diagnosis or treatment where recurrence has not been ruled out
• Pelvic pain that is new, unilateral, or associated with a mass

A 2022 review in the British Journal of General Practice noted that postmenopausal bleeding has an approximately 10% chance of representing endometrial cancer, which is why any bleeding in a woman who has not had a period for 12 or more months requires prompt investigation rather than reassurance.